Cellectis S.A. (NASDAQ:CLLS – Get Rating) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.42 and traded as high as $2.51. Cellectis shares last traded at $2.50, with a volume of 155,024 shares changing hands.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on the stock. Citigroup lifted their price objective on shares of Cellectis from $34.00 to $36.00 in a report on Thursday, August 18th. StockNews.com downgraded shares of Cellectis from a “hold” rating to a “sell” rating in a report on Friday. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $15.17.
Cellectis Stock Up 15.2 %
The company has a quick ratio of 2.65, a current ratio of 2.65 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $113.93 million, a price-to-earnings ratio of -1.09 and a beta of 2.01. The stock’s fifty day moving average price is $2.42 and its 200-day moving average price is $2.89.
Institutional Trading of Cellectis
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia.
- Get a free copy of the StockNews.com research report on Cellectis (CLLS)
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.